# Doxil, Gemcitabine, and Velcade (PS341) in Advanced Cancer Patients

> **NCT00500422** · PHASE1 · COMPLETED · sponsor: **M.D. Anderson Cancer Center** · enrollment: 134 (actual)

## Conditions studied

- Solid Tumors

## Interventions

- **DRUG:** Doxil
- **DRUG:** Gemcitabine
- **DRUG:** Velcade

## Key facts

- **NCT ID:** NCT00500422
- **Lead sponsor:** M.D. Anderson Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-01
- **Primary completion:** 2012-11
- **Final completion:** 2012-11
- **Target enrollment:** 134 (ACTUAL)
- **Last updated:** 2013-02-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00500422

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00500422, "Doxil, Gemcitabine, and Velcade (PS341) in Advanced Cancer Patients". Retrieved via AI Analytics 2026-08-18 from https://api.ai-analytics.org/clinical/NCT00500422. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*